128 related articles for article (PubMed ID: 11963641)
1. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.
Klotz U
Arzneimittelforschung; 2002; 52(3):155-61. PubMed ID: 11963641
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
3. MDR- and CYP3A4-mediated drug-herbal interactions.
Pal D; Mitra AK
Life Sci; 2006 Mar; 78(18):2131-45. PubMed ID: 16442130
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions of drugs with St John's wort.
Zhou S; Chan E; Pan SQ; Huang M; Lee EJ
J Psychopharmacol; 2004 Jun; 18(2):262-76. PubMed ID: 15260917
[TBL] [Abstract][Full Text] [Related]
5. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice.
Bailey DG; Bend JR; Arnold JM; Tran LT; Spence JD
Clin Pharmacol Ther; 1996 Jul; 60(1):25-33. PubMed ID: 8689808
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions with cisapride: clinical implications.
Michalets EL; Williams CR
Clin Pharmacokinet; 2000 Jul; 39(1):49-75. PubMed ID: 10926350
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Dresser GK; Spence JD; Bailey DG
Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
[TBL] [Abstract][Full Text] [Related]
8. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
[TBL] [Abstract][Full Text] [Related]
9. Potential for interaction of kava and St. John's wort with drugs.
Singh YN
J Ethnopharmacol; 2005 Aug; 100(1-2):108-13. PubMed ID: 16005588
[TBL] [Abstract][Full Text] [Related]
10. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
11. Role of P-glycoprotein in statin drug interactions.
Holtzman CW; Wiggins BS; Spinler SA
Pharmacotherapy; 2006 Nov; 26(11):1601-7. PubMed ID: 17064205
[TBL] [Abstract][Full Text] [Related]
12. Lercanidipine in the treatment of hypertension.
Beckey C; Lundy A; Lutfi N
Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of calcium antagonists under development.
Abernethy DR; Schwartz JB
Clin Pharmacokinet; 1988 Jul; 15(1):1-14. PubMed ID: 3042243
[TBL] [Abstract][Full Text] [Related]
14. Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
Machavaram KK; Gundu J; Yamsani MR
Pharmazie; 2004 Dec; 59(12):957-60. PubMed ID: 15638086
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223
[TBL] [Abstract][Full Text] [Related]
16. Grape fruit juice-drug interactions.
Arayne MS; Sultana N; Bibi Z
Pak J Pharm Sci; 2005 Oct; 18(4):45-57. PubMed ID: 16380358
[TBL] [Abstract][Full Text] [Related]
17. Pattern of interaction between dihydropyridine calcium antagonists and cationic amphiphilic drugs in isolated guinea-pig left atria.
Schröder F; Herzig S
Arzneimittelforschung; 1993 Nov; 43(11):1148-51. PubMed ID: 8292056
[TBL] [Abstract][Full Text] [Related]
18. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study.
Wang XD; Li JL; Lu Y; Chen X; Huang M; Chowbay B; Zhou SF
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):534-44. PubMed ID: 17339138
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
Barrios V; Escobar C; de la Figuera M; Llisterri JL; Honorato J; Segura J; Calderón A
Cardiovasc Ther; 2008; 26(1):2-9. PubMed ID: 18466416
[TBL] [Abstract][Full Text] [Related]
20. [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect].
Heynen G
Schweiz Rundsch Med Prax; 1992 Feb; 81(7):199-203. PubMed ID: 1531545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
